TENOFOVIR DISOPROXIL FUMARATE RELEASE FROM GLUTARALDEHYDE CROSS-LINKED CHITOSAN/Β-CYCLODEXTRIN HYDROGEL
Abstract
Keywords
Supporting Institution
Project Number
Thanks
References
- WHO, 2021a. “World Health Organisation, Coronavirus (COVID-19)”, https://covid19.who.int/ (Erişim tarihi: 29.10.2021)
- K. Kurt, L. Dönbak, A. Kayraldız, Tenofovir Disoproxil Fumarate in the Treatment of AIDS, Archives Medical Review Journal, 24 (2015) 119-134.
- WHO, 2021b. “World Health Organisation, Hepatitis B”, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (Erişim tarihi: 29.10.2021)
- UNAIDS, 2021. “The Joint United Nations Programme on HIV/AIDS, Global HIV & AIDS statistics-Fact sheet”, https://www.unaids.org/en/resources/fact-sheet (Erişim tarihi: 02.12.2021)
- D. Yu, J. Heathcote, Tenofovir in the treatment of chronic hepatitis B, Therapy, 8 (2011) 527-544.
- J.E. Gallant, S. Deresinski, Tenofovir disoproxil fumarate, Clin. Infect. Dis., 37 (2003) 944-950.
- S.M. Ecin, N. Çalık Başaran, M. Aladağ, Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients, Acta Medica, 51 (2020) 9-14.
- J. Li, D.H. Zhang, X.X. Zhang, The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report, Infect. Drug Resist., 14 (2021) 1013-1017.
Details
Primary Language
English
Subjects
Macromolecular Materials, Characterisation of Biological Macromolecules
Journal Section
Dissertation
Authors
Nuh Yaman
0000-0002-2550-469X
Türkiye
Sevil Erdogan
*
0000-0001-9148-911X
Türkiye
Betül Taşdelen
0000-0002-6541-7857
Türkiye
Publication Date
April 1, 2024
Submission Date
August 2, 2023
Acceptance Date
December 9, 2023
Published in Issue
Year 2024 Volume: 52 Number: 2